SP-8356, a Novel Inhibitor of CD147-Cyclophilin A Interactions, Reduces Plaque Progression and Stabilizes Vulnerable Plaques in apoE-Deficient Mice
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pahk, Kisoo | - |
dc.contributor.author | Joung, Chanmin | - |
dc.contributor.author | Song, Hwa Young | - |
dc.contributor.author | Kim, Sungeun | - |
dc.contributor.author | Kim, Won-Ki | - |
dc.date.accessioned | 2021-08-31T14:46:53Z | - |
dc.date.available | 2021-08-31T14:46:53Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2020-01-01 | - |
dc.identifier.issn | 1661-6596 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/58382 | - |
dc.description.abstract | Interactions between CD147 and cyclophilin A (CypA) promote plaque rupture that causes atherosclerosis-related cardiovascular events, such as myocardial infarction and stroke. Here, we investigated whether SP-8356 ((1S,5R)-4-(3,4-dihydroxy-5-methoxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one), a novel drug, can exert therapeutic effects against plaque progression and instability through disruption of CD147-CypA interactions in apolipoprotein E-deficient (ApoE KO) mice. Immunocytochemistry and immunoprecipitation analyses were performed to assess the effects of SP-8356 on CD147-CypA interactions. Advanced plaques were induced in ApoE KO mice via partial ligation of the right carotid artery coupled with an atherogenic diet, and SP-8356 (50 mg/kg) orally administrated daily one day after carotid artery ligation for three weeks. The anti-atherosclerotic effect of SP-8356 was assessed using histological and molecular approaches. SP-8356 interfered with CD147-CypA interactions and attenuated matrix metalloproteinase-9 activation. Moreover, SP-8356 induced a decreased in atherosclerotic plaque size in ApoE KO mice and stabilized plaque vulnerability by reducing the necrotic lipid core, suppressing macrophage infiltration, and enhancing fibrous cap thickness through increasing the content of vascular smooth muscle cells. SP-8356 exerts remarkable anti-atherosclerotic effects by suppressing plaque development and improving plaque stability through inhibiting CD147-CypA interactions. Our novel findings support the potential utility of SP-8356 as a therapeutic agent for atherosclerotic plaque. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.subject | MATRIX METALLOPROTEINASE INDUCER | - |
dc.subject | ANIMAL-MODELS | - |
dc.subject | ATHEROSCLEROSIS | - |
dc.subject | EMMPRIN | - |
dc.subject | CYCLOPHILIN | - |
dc.subject | CD147 | - |
dc.subject | MMP-9 | - |
dc.subject | MATRIX-METALLOPROTEINASE-9 | - |
dc.subject | RISK | - |
dc.subject | PLASMINOGEN | - |
dc.title | SP-8356, a Novel Inhibitor of CD147-Cyclophilin A Interactions, Reduces Plaque Progression and Stabilizes Vulnerable Plaques in apoE-Deficient Mice | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Sungeun | - |
dc.contributor.affiliatedAuthor | Kim, Won-Ki | - |
dc.identifier.doi | 10.3390/ijms21010095 | - |
dc.identifier.scopusid | 2-s2.0-85076916352 | - |
dc.identifier.wosid | 000515378000095 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, v.21, no.1 | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | - |
dc.citation.title | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | - |
dc.citation.volume | 21 | - |
dc.citation.number | 1 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.subject.keywordPlus | MATRIX METALLOPROTEINASE INDUCER | - |
dc.subject.keywordPlus | ANIMAL-MODELS | - |
dc.subject.keywordPlus | ATHEROSCLEROSIS | - |
dc.subject.keywordPlus | EMMPRIN | - |
dc.subject.keywordPlus | CYCLOPHILIN | - |
dc.subject.keywordPlus | CD147 | - |
dc.subject.keywordPlus | MMP-9 | - |
dc.subject.keywordPlus | MATRIX-METALLOPROTEINASE-9 | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | PLASMINOGEN | - |
dc.subject.keywordAuthor | atherosclerosis | - |
dc.subject.keywordAuthor | plaque | - |
dc.subject.keywordAuthor | plaque vulnerability | - |
dc.subject.keywordAuthor | cluster of differentiation 147 (CD147) | - |
dc.subject.keywordAuthor | matrix metalloproteinase | - |
dc.subject.keywordAuthor | matrix metalloproteinase-9 (MMP-9) | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.